CD19 and congenital rubella syndrome: To visualize the utility of risk stratification by key clinical variables identified in the analyses for guiding potential CMV screening, we generated stratified cumulative incidence plots of CMV reactivation by BCMA- versus CD19-CARTx, >3 days of corticosteroids for CRS/ICANS, a composite of BCMA-CARTx and corticosteroid use >3 days, and CMV-CMI values (Figure 5).